Prostate cancer spread and immune system study
Part of Cancer clinical trials.
This study is looking at how prostate cancer that has spread changes over time, especially in terms of the immune system. It uses advanced tissue analysis to understand the disease better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a man between 18 and 85 years old.
- Your prostate cancer must be a specific type (adenocarcinoma, ductal adenocarcinoma, or intraductal carcinoma) that has spread to other parts of the body.
- You must not have had any prior treatment for your prostate cancer.
- You should be in relatively good health (able to do daily activities, with adequate blood counts and organ function).
- You must be willing to provide a tissue sample and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving intense hormone therapy along with either radiation or surgery can help men with prostate cancer that has spread to a limited number of spots (10 or fewer) but not to organs like the liver or lungs. The goal is to treat both the main tumor and the visible metastatic spots more aggressively.
This trial tests a shorter course of hormone therapy plus targeted radiation for prostate cancer that has spread to a few spots (oligometastatic). The goal is to see if less hormone therapy can still control the cancer effectively.
This trial tests two newer treatments—targeted radiation (SABR) or a special radioactive drug (Lu-177 PSMA-617)—added to standard hormone therapy for men with prostate cancer that has spread. The goal is to see if these additional treatments help control the cancer better.
This trial studies the “microenvironment” around prostate cancer metastases, using specimens taken during biopsy and other scans. It may help researchers understand what drives prostate cancer spread and improve future treatment choices.
This trial tests whether giving radiotherapy to the prostate and a few cancer spots elsewhere in the body can help control low-spread prostate cancer. It is for people who have not had any previous prostate cancer treatment.
This trial tests adding abiraterone (a hormone therapy pill) and prednisone to standard hormone therapy (ADT) for prostate cancer that has spread to nearby lymph nodes but is too small to see on regular scans. The goal is to see if this combination works better than ADT alone.
Hear when a new Metastatic Hormone-Sensitive Prostate Cance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.